Mellor AL and Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today1999; 20:469–473.
Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med2002; 196:459–468.
Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol2003; 24:242–248.
Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science2002; 297:1867–1870.
Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood2004; 103:4619–4621.
Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med2003; 9:1269–1274.
Curti A, Aluigi M, Pandolfi S, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia2007; 21:353–355.
Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol2002; 2:389–400.
O'Garra A and Vieira P. Regulatory T cells and the mechanisms of immune system control. Nat Med2004; 10:801–805.
Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev2001; 182:18–32.
Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med2004; 10:942–949.
Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res2003; 9:606–612.
Terabe M and Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol2004; 16:157–162.
Kudo Y, Boyd CA, Spyropoulou I, et al. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. J Reprod Immunol2004; 61:87–98.
Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science1998; 281:1191–1193.
Heikkinen J, Mottonen M, Alanen A, Lassila O. Phenotypic characterization of regulatory T cells in the human decidua. Clin Exp Immunol2004; 136:373–378.
Bozza S, Fallarino F, Pitzurra L, et al. A crucial role for tryptophan catabolism at the host/Candida albicans interface. J Immunol2005; 174:2910–2918.
Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest2004; 114:280–290.
Munn DH and Mellor AL. IDO and tolerance to tumors. Trends Mol Med2004; 10:15–18.
Aluigi M, Fogli M, Curti A, et al. Nucleofection is an efficient non-viral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells2006; 24:454–461.
Curti A, Ratta M, Corinti S, et al. Interleukin-11 induces Th2 polarization of human CD4+ T cells. Blood2001; 97:2758–2763.
Pileri S, Gerdes J, Rivano MT, et al. Immunohistochemical determination of growth fractions in human permanent cell lines and lymphoid tumors: a critical comparison of the monoclonal antibodies OKT9 and Ki-67. Br J Haematol1987; 65:271–276.
Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol2002; 168:3771–3776.
Fontenot JD and Rudensky AY. A well-adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol2005; 6:321–337.
Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25− lymphocytes is thymus and proliferation independent. Cancer Res2006; 66:4488–4495.
Mellor AL and Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol2004; 4:762–774.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol2002; 3:991–998.
Curti A, Pandolfi S, Aluigi M, et al. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Exp Hematol2005; 33:1521–1530.
Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol2003; 4:1206–1212.
Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ2002; 9:1069–1077.
Mahnke K, Qian Y, Knop J, Enk AH. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood2003; 101:4862–4869.
Thorstenson KM and Khoruts A. Generation of anergic and potentially immunoregulatory CD25+CD4+ T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol2001; 167:188–195.
Buggins AG, Milojkovic D, Arno MJ, et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-κB, c-Myc, and pRb pathways. J Immunol2001; 167:6021–6030.
Buggins AG, Lea N, Gäken J, et al. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood1999; 94:3479–3490.
Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med2003; 198:1875–1886.
Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T-cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol2006; 176:6752–6761.
Bronte V and Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol2005; 5:641–654.